ALXO Q2 2023 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$34M

EPS (Diluted)

$-0.84

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$246M

Total Liabilities

$33M

Stockholders' Equity

$213M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$34M	-8.8%
Net Income	-$34M	-$33M	-3.8%